Afatinib-Induced Acute Fatal Pneumonitis in Metastatic Lung Adenocarcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Afatinib is an oral tyrosine kinase inhibitor (TKI) that inhibit Endothelial Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and HER4. The common side effects of EGFR TKI are rash, acne, di-arrhea, stomatitis, pruritus, nausea, and loss of appetite. Drug induced pneumonitis is the less common adverse ef-fects of EGFR TKI. Afatinib, 2nd generation EGFR TKI is anticipated to overcome drug resistance from 1st genera-tion EGFR TKI according to preclinical study, and several studies are being conducted to compare clinical efficacy between 1st and 2nd EGFR TKI. Several cases of rug induced acute fatal pneumonitis were reported after use of er-lotinib or gefitinib. However, a case of acute fatal pneumonitis associated with afatinib was note reported except drug induced pneumonitis in other clinical study. Here, we present a cases of acute severe pneumonitis related with afatinib in metastatic lung adenocarcinoma with literature review.
Abstract
Afatinib is an oral tyrosine kinase inhibitor (TKI) that inhibit Endothelial Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and HER4. The common side effects of EGFR TKI are rash, acne, di-arrhea, stomatitis, pruritus, nausea, and loss of appetite. Drug induced pneumonitis is the less common adverse ef-fects of EGFR TKI. Afatinib, 2nd generation EGFR TKI is anticipated to overcome drug resistance from 1st genera-tion EGFR TKI according to preclinical study, and several studies are being conducted to compare clinical efficacy between 1st and 2nd EGFR TKI. Several cases of rug induced acute fatal pneumonitis were reported after use of er-lotinib or gefitinib. However, a case of acute fatal pneumonitis associated with afatinib was note reported except drug induced pneumonitis in other clinical study. Here, we present a cases of acute severe pneumonitis related with afatinib in metastatic lung adenocarcinoma with literature review.
참고문헌 (10)
- Pao W, "Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain", PLoS Med, 2, pp.e73~ (2005)
- Soria JC, "Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial", Lancet Oncol, 16, pp.897~907 (2015)
- Yang JC, "Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial", Lancet Oncol, 13, pp.539~548 (2012)
- Zhang Y, "Successful treatment of gefitinib-induced acute interstitial pneumonitis with corticosteroid and non-invasive BIPAP-ventilation", J Thorac Dis, 4, pp.316~319 (2012)
- Lai YC, "Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review", Int J Clin Pharmacol Ther, 49, pp.461~466 (2011)
- Chang SC, "Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia", J Thorac Oncol, 5, pp.1105~1106 (2010)
- Qi WX, "Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a metaanalysis of 24 phase III clinical trials", J Chemother, 27, pp.40~51 (2015)
- Shi L, "Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials", Lung Cancer, 83, pp.231~239 (2014)
- Suzuki H, "Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis", Cancer Res, 63, pp.5054~5059 (2003)
- Ando M, "Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib", J Clin Oncol, 24, pp.2549~2556 (2006)